India Oncology Diagnostics & Cancer Screening Center Network Feasibility Study, Oncology Diagnostics Market Outlook

Executive Viability Abstract

This bankable feasibility study evaluates the establishment of a multi-center Oncology Diagnostics and Cancer Screening network in India. With a projected investment of INR 1.45 Billion for the initial phase (3 Hubs, 6 Spokes), the project leverages the 12.5% CAGR in Indian oncology diagnostics. Key financial indicators show a 24.8% IRR and a 4.2-year payback period, supported by high-demand modalities such as PET-CT and Next-Generation Sequencing (NGS).

## Executive Feasibility Thesis The Indian oncology diagnostics market is valued at approximately USD 1.2 Billion, characterized by a significant supply-demand gap in Tier-2 and Tier-3 cities. The feasibility of this network rests on a 'Hub-and-Spoke' model where high-capital molecular imaging and genomics are centralized (Hubs), while routine screenings and biopsies are decentralized (Spokes). **Key Assumptions:** - **Target Market Size:** Catchment area of 15 million population across three regional clusters. - **Cost of Capital (WACC):** 12.5%, reflecting India's current lending rates for healthcare infrastructure and equity risk premium. - **Capacity Utilization:** Ramp-up from 30% in Year 1 to a terminal utilization of 75% by Year 5. - **Inflation Index:** 5.5% annually applied to Opex and pricing adjustments. ## Technical Feasibility & Operational Specifications The network will deploy a tiered technology stack to ensure clinical precision and cost-efficiency. - **Hub Specifications:** Each Hub will feature a Digital PET-CT (Time-of-Flight technology) for metabolic imaging and a high-throughput Next-Generation Sequencing (NGS) platform for liquid biopsies and tissue profiling. - **Spoke Specifications:** Equipped with 3D Digital Mammography (Tomosynthesis), High-end Ultrasound with Elastography, and Digital Pathology scanners to facilitate remote reporting by sub-specialized oncopathologists. - **Operational Integration:** A cloud-native RIS/PACS (Radiology Information System / Picture Archiving and Communication System) will enable real-time collaboration between hubs and spokes, reducing Turnaround Time (TAT) for reports from the industry average of 48 hours to 18 hours. ## Detailed Capital Expenditure (Capex) Costs are estimated for a single 'Hub' unit. All figures are in INR (Millions). | Item | Unit Cost (INR M) | Reasoning | | :--- | :--- | :--- | | **Digital PET-CT System** | 85.0 | High-sensitivity scanners required for early lesion detection (Stage 0/1). | | **3T MRI (Onco-configured)** | 75.0 | Essential for neuro and prostate oncology imaging. | | **NGS Platform (Illumina/Ion Torrent)** | 35.0 | Capability for 500+ gene panel testing. | | **Cyclotron-Link/Hot Lab** | 12.0 | Lead shielding and synthesis modules for F18-FDG tracers. | | **Facility Interior & Lead Shielding** | 25.0 | Specialized AERB-compliant radiation shielding for PET/CT bunkers. | | **Digital Mammography (3D)** | 18.0 | Standard of care for breast cancer screening programs. | | **Initial Working Capital** | 20.0 | Covering 6 months of Opex during the brand-building phase. | | **Total Per Hub** | **270.0** | Total Capex for 3 Hubs + 6 Spokes is estimated at INR 1,450 Million. | ## Realistic Operating Expenditure (Opex) Annualized projections per Hub location based on local market labor and consumable rates. - **Specialized Manpower (INR 42M/yr):** Includes 2 Nuclear Medicine Physicians (INR 12M), 2 Onco-Radiologists (INR 10M), 1 Molecular Pathologist (INR 5M), and specialized technicians/nurses (INR 15M). - **Consumables & Reagents (28% of Gross Revenue):** High-cost items include FDG isotopes (INR 15,000 per dose) and NGS flow cells/reagents. - **AMC/CMC (INR 18M/yr):** Annual Maintenance Contracts at 7% of equipment cost, commencing post-warranty in Year 2. - **Power & Utilities (INR 6M/yr):** Reflecting high-energy requirements for MRI chillers and PET-CT cooling systems. - **Marketing & Physician Outreach (INR 12M/yr):** Essential for B2B referral building with local oncologists. ## Financial Model & Sensitivity Range on ROI/IRR The project assumes a 7-year appraisal period with a terminal value based on a 6x EV/EBITDA multiple. **Base Case:** - **IRR:** 24.8% - **NPV:** INR 480 Million (at 12.5% discount rate) - **Assumptions:** 60% average utilization, stable reagent pricing. **Sensitivity Analysis:** | Scenario | Variable Change | Projected IRR | Impact Analysis | | :--- | :--- | :--- | :--- | | **Optimistic** | +15% Patient Yield / -5% Opex | 31.2% | Driven by rapid adoption of preventive screening packages. | | **Pessimistic** | -10% Pricing Power / +10% Reagent Cost | 16.5% | Occurs if government price caps (CGHS) are expanded significantly. | | **Technological Shift** | +20% Capex for Upgrades | 21.0% | Impact of premature obsolescence of imaging hardware. | ## Regulatory & Environmental Compliance Frameworks Navigating the Indian regulatory landscape is critical for bankability. - **AERB (Atomic Energy Regulatory Board):** Mandatory site layout approval and commissioning license for PET-CT and X-ray equipment. - **PNDT Act:** Registration for all Ultrasound/Imaging equipment to prevent gender selection, involving rigorous record-keeping. - **Biomedical Waste Management Rules (2016):** Contractual alignment with common treatment facilities for cytotoxic and radioactive waste disposal. - **NABL (ISO 15189):** National Accreditation Board for Testing and Calibration Laboratories certification required within 12 months of launch to ensure quality reimbursement from private insurers. - **NABH (Imaging):** Essential for empanelment with the Ayushman Bharat (PM-JAY) scheme for high-volume public-private partnership revenue. ## Strategic Takeaways 1. **Early Entry Advantage:** Establishing high-end molecular diagnostics in Tier-2 hubs creates a defensive moat against localized labs that lack capital for PET-CT or NGS. 2. **Asset-Light Spokes:** Utilizing the spokes as collection and primary screening points ensures a wide funnel for the high-margin Hub services. 3. **Risk Mitigation:** Sensitivity analysis confirms that even in a pessimistic pricing scenario, the IRR remains above the WACC (12.5%), suggesting a resilient business model. 4. **Scalability:** The centralized RIS/PACS allows for the addition of 'Satellite' centers with minimal incremental overhead, enhancing long-term enterprise value.